New shop levitra australia online tablets-au.com with a lot of generic and brand drugs with cheap price and fast delivery.
Product information- biostate
NAME OF THE MEDICINE
Human coagulation factor VIII and human von Willebrand factor complex, powder for
Biostate® is a high purity, sterile, powder for injection containing a human coagulation factor
VIII (FVIII) and human von Willebrand factor (VWF) complex. Biostate® is manufactured
from human plasma collected by the Australian Red Cross Blood Service. It is intended for
intravenous administration. The FVIII/VWF complex in Biostate® is purified from
cryoprecipitate using selective precipitation and size exclusion chromatography steps. The
Biostate® manufacturing process includes solvent detergent (tributyl phosphate and
polysorbate 80) and dry heat treatment (80°C for 72 hours) steps to reduce the potential for
virus transmission. The solvent detergent, dry heat treatment, and partitioning steps used in the
manufacture of Biostate® have been demonstrated to be effective virus inactivation/removal
steps in vitro for the relevant viruses, human immunodeficiency virus (HIV) and hepatitis A
virus (HAV), and also with model viruses for hepatitis B virus (HBV) and hepatitis C virus
(HCV). The manufacturing process also contributes to inactivation/removal of human
Von Willebrand Factor
Following reconstitution, 1 mL of Biostate® contains:
• Biostate® 50 IU FVIII/mL: approximately 100 IU of human plasma derived VWF
• Biostate® 100 IU FVIII/mL: approximately 200 IU of human plasma derived VWF.
The VWF:RCo activity is determined using the WHO standard for VWF. The specific VWF
activity of Biostate® prior to the addition of human albumin as a stabiliser is approximately
Following reconstitution, 1 mL of Biostate® contains:
• Biostate® 50 IU FVIII/mL: approximately 50 IU of human plasma derived coagulation
• Biostate® 100 IU FVIII/mL: approximately 100 IU of human plasma derived
The FVIII potency (IU) is determined using the European Pharmacopoeia chromogenic assay.
The specific FVIII activity of Biostate® prior to the addition of human albumin as a stabiliser is
approximately 70 IU of FVIII/mg protein.
Biostate® contains other proteins such as fibrinogen, fibronectin, immunoglobulins (IgA, IgM,
IgG) and transforming growth factor β (TGF-β) all of which are present at significantly lower levels than in normal plasma.
Biostate® is available in two different concentrations (strengths) and in three different
presentations as detailed in Tab le 1
. The amount of VWF:RCo in the final product is
dependent on the method of preparation of the cryoprecipitate, and this influences the
VWF:RCo:FVIII ratio. Biostate® contains VWF:RCo and FVIII in a ratio of 2:1.
Tab le 1: Biostate® Composition*
50 IU FVIII/mL / 100 IU VWF/mL
100 IU FVIII/mL / 200 IU
250 IU FVIII/
500 IU FVIII/
1000 IU FVIII/
500 IU VWF
1000 IU VWF
2000 IU VWF
Active ingredients IU/vial
Reconstitution Volume (mL)
VWF:RCo – VWF ristocetin cofactor activity.
The Biostate® FVIII/VWF complex consists of two different noncovalently bound proteins:
FVIII and VWF. FVIII is an essential cofactor in activation of factor X leading ultimately to
the formation of thrombin and fibrin. The activity of FVIII is measured as FVIII coagulation
activity (FVIII:C). VWF promotes platelet aggregation and platelet adhesion on damaged
vascular endothelium; it also serves as a stabilising carrier protein for the procoagulant protein
FVIII. The activity of VWF is measured as von Willebrand factor ristocetin cofactor activity
Von Willebrand disease (VWD) is an autosomally-inherited congenital bleeding disorder in
which there is a deficiency or dysfunction of VWF. A reduction in VWF concentration in the
bloodstream results in low FVIII activity and abnormal platelet function as the platelets are
prevented from adhering to sub-endothelial tissue. As a result, excessive bleeding may occur.
The VWF:RCo activity in Biostate® exists in a 2:1 ratio with FVIII:C activity. Biostate® has
been demonstrated to contain the high molecular weight (HMW) multimers of VWF. HMW
multimers are considered to be important for correcting the haemostatic defect in patients with
VWD as they are important for platelet adhesion.
Haemophilia A is an X-linked recessive blood coagulation disorder. It is caused by reduced
FVIII activity through either insufficient or abnormal synthesis of the FVIII protein. FVIII is a
cofactor for activated factor IX, and accelerates the conversion of factor X to activated factor
X. Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen
Von Willebrand Factor
The pharmacokinetics of the product have been evaluated in VWD patients in the non-
Based on a pharmacokinetic study with 14 subjects with VWD, the following pharmacokinetic
characteristics for VWF:RCo, VWF:Ag, and VWF:CB were observed following a single
intravenous infusion of 80 IU VWF:RCo/kg.
Table 2: Pharmacokinetics data for VWF:RCo, VWF:Ag, and VWF:CB
a median AUC = area under the curve; Cmax = maximum plasma concentration; Cmin = minimum plasma concentration; IU = International Unit; MRT = mean residence time; N = number of subjects; SD = standard deviation; Tmax = time the maximum concentration occurs; Vss = volume of distribution at steady state; VWF:Ag = von Willebrand factor: Antigen; VWF:CB = von Willebrand factor: Collagen Binding; VWF:RCo = von Willebrand factor: Ristocetin Cofactor.
Peak plasma levels of VWF usually occur within a mean time of 18 minutes (median
Similar results for both VWF and FVIII PK parameters were found when assessed after 6
The pharmacokinetics of the product have been evaluated in haemophilia A patients in the non-
Based on a pharmacokinetic study with 16 subjects with haemophilia A, the following
pharmacokinetic characteristics for FVIII:C were observed following a single intravenous
Table 3: Pharmacokinetics data for FVIII:C
AUC = area under the curve; Cmax = maximum plasma concentration; Cmin = minimum plasma concentration; IU = International Unit; MRT = mean residence time; N = number of subjects; SD = standard deviation; Tmax = time the maximum concentration occurs; Vss = volume of distribution at steady state; FVIII:C = Factor VIII: Coagulant.
Peak plasma levels of FVIII usually occur within a mean time of 49 minutes (median
Similar pharmacokinetic results, including FVIII half-life, were found when PK parameters
were assessed 6 months after the initial PK study. VWF PK parameters were not measured in
the initial assessment or the repeat assessment after 6 months.
No pharmacokinetic data are available in patients younger than 12 years.
A total of 168 subjects were exposed in the prospective clinical studies, including 111 subjects
with haemophilia A and 57 subjects with VWD. Among these exposed subjects, 5 subjects
with haemophilia A and 3 subjects with VWD were adolescents, i.e. aged 12 – <18 years, and
1 subject with VWD was a 3-year-old child.
In addition, efficacy and safety data in VWD subjects were collected in 2 published
investigator-led studies that included 43 adult VWD subjects (Shortt study) and 43
adolescents and children (Howman study).
Von Willebrand disease
Efficacy in the control of non-surgical and surgical bleeding was assessed in two open-label
non-controlled trials. A 4-point rating scale was used in both trials: None – no control of
bleeding; Moderate – moderate control of bleeding, other treatment also required; Good –
slight oozing, partial but adequate control of bleeding; Excellent – haemostasis achieved.
In the first trial, with a focus on non-surgical bleeds (NSB), the haemostatic efficacy for 98.3%
of 405 evaluable NSB were assessed by the investigator as excellent or good and 1.7% as
moderate. During the study 8 subjects experienced 125 major NSBs, of which 7 were mucosal
bleeds. The investigator’s overall assessment was excellent for 1 and moderate for the other 6
major mucosal bleeds which were uterine bleeds; although for four of the later 6 bleeds the
investigator had assessed efficacy as good on at least 1 day.
In the second trial the focus was on surgery. In 9 patients undergoing 10 major surgical
procedures, the efficacy was excellent or good in 10 (100%). In 11 patients undergoing
15 minor surgical procedures, haemostatic efficacy was excellent in 14 (93%) and good in
The mean dose to achieve haemostasis was 27 IU FVIII:C/kg/day for a median 2 days in
non-surgical bleeding, 33 IU FVIII:C/kg/day for a median 2 days in minor surgery and 41 IU
FVIII:C/kg/day for a median 7.5 days in major surgery.
In a retrospective review of surgical bleeding in 43 adult patients undergoing 58 procedures,
the haemostatic efficacy was excellent or good in 100% of procedures. Efficacy in the VWD
Type 3 patients (n=5) was rated as excellent in 55%. The mean dose to achieve haemostasis
was 29 IU FVIII:C/kg/day for a mean 2 days (range 1–4) in minor dental procedures and 5
days (range 1–13) in major surgery. There was some concomitant use of tranexamic acid and
In a second retrospective review in children and adolescents, 42 surgical events were treated:
10 major events in 10 subjects and 32 minor surgical events in 21 subjects. Four episodes of
post-surgical bleeding events were also treated in 4 subjects, who had not received the product
to prevent bleeding during the procedure. A total of 72 NSB events were treated: 46
mucocutaneous in 11 subjects and 26 musculoskeletal or soft tissue bleedings in 13 subjects.
Only tranexamic acid was used as an adjunctive therapy in these subjects.
The haemostatic efficacy for all surgical events was excellent or good in approximately 90% of
events (90% major and 91% of minor surgical events). Haemostatic efficacy for all NSB
events was rated as excellent or good in 94% of events, and within Type 3 VWD subjects in
The mean daily dose was 51 IU FVIII/kg (range: 13–151 IU FVIII/kg) for major surgery with
a median treatment duration of 7 days (range: 1–24 days) and 45 IU FVIII/kg (range: 14–
76 IU FVIII/kg) for minor surgery with a median treatment duration of 3 days (range: 1–8
days). For NSB events, the mean daily dose was 45 IU FVIII/kg (range: 16–192 IU FVIII/kg)
with a median treatment duration of 1 day (range: 1–13 days).
Efficacy and safety in acquired VWD has not been established.
Adverse reactions encountered during the clinical trials in VWD patients are included under
In an open study in adult subjects with haemophilia A, 81 subjects were treated with
77 subjects completing 6 months of treatment. Patients were treated either on-demand
(including the prevention of bleeding in relation to surgery) or as prophylaxis. Of
656 evaluable bleeding events 96.4% were assessed as excellent or good, 3.5% as moderate
and 0.2% as none (one event, no efficacy).
During the study, a total of 37 surgical events occurred in 20 subjects; 12 events were major
and 25 minor. Investigator’s assessment of haemostatic efficacy at discharge was reported as
excellent for 8 major and 10 minor surgical events, and as good for 2 major surgical events.
Adverse reactions encountered during the clinical trials in haemophilia A patients are included
under ADVERSE EFFECTS
Efficacy and safety have not been studied in previously untreated patients.
• the treatment of bleeding episodes including surgical bleeding in patients with von
Willebrand disease when desmopressin (DDAVP) treatment is ineffective or
• the treatment and prophylaxis of bleeding associated with FVIII deficiency due to
Biostate® is contraindicated in individuals with a history of anaphylactic or severe systemic
response to coagulation FVIII and/or VWF preparations. Also it is contraindicated in
individuals with a known hypersensitivity to any of its components.
Biostate® should be used with caution in patients with a known allergy to FVIII and/or VWF
concentrates, or human albumin. Allergic, anaphylactic reactions or fever are rarely observed
in patients receiving FVIII preparations. If any adverse event occurs while Biostate® is being
administered, the rate of injection should be slowed or stopped to alleviate symptoms.
Patients should be informed of the early signs of hypersensitivity reactions such as allergic skin
reactions including hives, generalised urticaria, tightness of the chest, wheezing, flushing,
hypotension and anaphylaxis. If these symptoms occur they should be advised to seek medical
opinion. In case of shock, the current medical standards for treatment of shock should be
The formation of neutralising antibodies (inhibitors) to FVIII is a known complication in the
management of individuals with haemophilia A. These inhibitors are immunoglobulins (usually
IgG) directed against the FVIII procoagulant activity. The inhibitor level in the plasma is
measured by the Bethesda assay (as Bethesda Units (BU) per mL). The risk of developing
inhibitors is correlated to the exposure to FVIII, this risk being highest within the first 20
exposure days. Rarely, inhibitors may develop after the first 100 exposure days.
Cases of recurrent inhibitor (low titre) have been observed after switching from one FVIII
product to another in previously treated patients with more than 100 exposure days who have
a previous history of inhibitor development. Therefore, it is recommended to monitor patients
carefully for inhibitor occurrence following any product switch.
In general, all patients treated with coagulation FVIII products should be carefully monitored
for the development of inhibitors by appropriate clinical observations and laboratory tests.
Patients with VWD, especially type 3 patients, may very rarely develop inhibitors to VWF. If
such inhibitors occur, the condition would manifest itself as an inadequate clinical response
such as bleeding not being controlled with an appropriate dose or the expected VWF:RCo
activity plasma levels not being attained. Such antibodies may occur in close association with
anaphylactic reactions. Therefore, patients experiencing anaphylactic reaction should be
evaluated for the presence of an inhibitor.
Thromboembolic events have been rarely reported in VWD patients receiving coagulation
factor replacement therapy, especially in the setting of known risk factors for thrombosis and
may be related to the generation of supranormal FVIII levels. In these patients, caution should
be exercised and antithrombotic measures should be considered.
This product is made from human plasma. Products made from human plasma may contain
infectious agents, such as viruses and theoretically Creutzfeldt-Jakob disease (CJD) agents that
can cause disease. The risk that such products will transmit an infectious agent has been
reduced by screening plasma donors for prior exposure to certain infectious agents and by
testing for the presence of certain viral markers.
In addition, virus removal and inactivation steps are included in the manufacturing process.
The current procedures applied in the manufacture of this product are effective against
enveloped viruses such as HIV, HBV and HCV viruses, and the non-enveloped virus HAV.
They are also known to contribute to the inactivation/removal of the non-enveloped virus,
Despite these safety measures, such products may still potentially transmit disease. There is
also the possibility that other known or unknown infectious agents may be present in such
Vaccination (e.g. hepatitis A and hepatitis B) should be considered where appropriate, for
patients in receipt of medicinal products manufactured from human plasma.
Effects on fertility
No reproductive toxicity studies have been conducted with Biostate®.
Use in pregnancy and lactation
The safety of this product for use in human pregnancy or during lactation has not been
The use of Biostate® in the paediatric population has not been established in clinical studies.
Use in the elderly
The safety of this product for use in the elderly population has not been established in
Carcinogenicity and genotoxicity
No carcinogenicity or genotoxicity studies have been conducted with Biostate®.
Effect on laboratory tests
FVIII and/or VWF are endogenous plasma proteins; no specific effects on laboratory tests are
INTERACTIONS WITH OTHER MEDICINES
The interaction of Biostate® with other medicines has not been established in specific studies.
The following tabulated adverse reactions are based on experience from scientific literature,
clinical trials and postmarketing experience from patients with haemophilia A and VWD.
The following standard categories of frequency are used where data are available:
frequency cannot be estimated from the available data
Tab le 4: Frequency of Adverse Reactions
Frequency in clinical
Hypersensitivity (including tachycardia, chest pain,
*Adverse events assessed as related to administration of the FVIII/VWF product.
Description of selected adverse reactions
Patients with haemophilia A may develop neutralising antibodies (inhibitors)
to FVIII. If such inhibitors occur, the condition will manifest itself as an insufficient clinical
response. In such cases, it is recommended that a specialised haemophilia centre be contacted.
There is no experience from clinical trials in previously untreated patients (PUPs). Therefore,
no valid figures on the incidence of clinically relevant specific inhibitors are currently available.
Patients with VWD, especially type 3 patients, may develop neutralising
antibodies (inhibitors) to VWF. If such inhibitors occur, the condition will manifest itself as an
inadequate clinical response. Such antibodies are precipitating and may occur concomitantly to
anaphylactic reactions. Therefore, patients experiencing an anaphylactic reaction should be
evaluated for the presence of an inhibitor. In all such cases, it is recommended that a
specialised haemophilia centre be contacted.
Hypersensitivity (allergic reactions):
Hypersensitivity or allergic reactions (which may include
angioedema, burning and stinging at the infusion site, chills, flushing, generalised urticaria,
headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest
(including chest pain and chest discomfort), back pain, tingling, vomiting, wheezing) have
been observed infrequently, and may in some cases progress to severe anaphylaxis (including
In patients with VWD, there is a risk of occurrence of
thromboembolic events, particularly in patients with known clinical or laboratory risk factors.
In patients receiving FVIII-containing VWF products, sustained excessive FVIII:C plasma
levels may increase the risk of thromboembolic events.
For safety with respect to transmissible agents, see PRECAUTIONS
There are insufficient data to estimate the frequency, type and severity of adverse reactions in
DOSAGE AND ADMINISTRATION
The dosage recommendations in Tab le 5
(VWD) and Tab le 6
(Haemophilia A) are general
guidelines for therapy. The exact loading and maintenance doses and dosing intervals should
be based on the patient’s clinical condition and response to therapy. Laboratory tests should be
performed to ensure that the desired plasma FVIII and VWF concentrations are achieved.
The active ingredients, VWF:RCo and FVIII are present in a ratio of 2:1.
Tab le 5: VWD Dosage Guidelines*
Target FVIII/VWF (%)
VWF/FVIII trough levels of >30% until
VWF/FVIII trough levels of >30% until
VWF/FVIII trough levels of >50% until
* For patients with severely reduced VWF levels, e.g. <10% of normal.
Doses may need to be adjusted down in patients with less severe VWF deficiencies to ensure that the
desired plasma concentrations of VWF and FVIII are achieved. It is recommended that plasma VWF and FVIII
concentrations are determined at suitable time intervals.
Tab le 6: Haemophilia A Dosage Guidelines
Target FVIII (%)
The ‘pre-op’ dose is the loading dose prior to surgery, day 1 is the day of surgery and trough levels need
to be maintained above target on day of surgery, and subsequently. For extensive dental clearance or surgery
higher levels may be necessary for longer periods of time. The use of an antifibrinolytic agent in support of
factor replacement is strongly recommended after dental extractions.
No studies using continuous infusion were carried out in patients. However, it is suggested
that this method is suitable for covering surgical procedures. The product required should be
reconstituted to the same volume and in the same diluent as for bolus infusion, and
administered using an infusion pump suitable for this volume. Reconstitution should be done
under aseptic conditions, and sterile integrity of the delivery device should be maintained.
It is recommended that plasma FVIII concentrations be determined in patient’s plasma at
suitable intervals and during the treatment of severe haemorrhage.
• Before reconstitution allow the vials of Biostate® and Water for Injections to reach a
• Remove the caps from the top of the Biostate® and Water for Injections vials.
• Apply a suitable antiseptic to the exposed part of the rubber stoppers of both Biostate®
and Water for Injections and allow to dry.
• Open the outer package of the Mix2Vial™ filter transfer set by peeling away the lid. If
the seal of the lid is not intact or there are any concerns about the integrity of the
Mix2Vial™, do not use it but return it to the Australian Red Cross Blood Service.
Place the Water for Injections on a level surface and hold the vial firmly. Take the
Mix2Vial™ together with its outer package and invert it. Push the blue plastic cannula
of the Mix2Vial™ firmly through the rubber stopper of the Water for Injections.
• While holding onto the vial of Water for Injections, carefully remove the outer package
from the Mix2Vial™, being careful to leave the Mix2Vial™ attached firmly to the
Water for Injections vial. Ensure that only the package and not the Mix2Vial™ is
• With the Biostate® vial held firmly on a level surface, invert the Water for Injections
with the Mix2Vial™ attached and push the transparent plastic cannula end of the
Mix2Vial™ firmly through the Biostate® stopper. The water will be drawn into the vial
by the vacuum within. In the unlikely event that the vial does not contain a
vacuum, do not use the product, but return it to the Australian Red Cross Blood
• With the Water for Injections and Biostate® vials still attached, gently swirl the product
vial to ensure the product is fully dissolved. Avoid excessive frothing. A clear or slightly
opalescent solution is usually obtained within 2 to 5 minutes. The solution should be
used as described in Administration
• Once the contents of the Biostate® vial are completely dissolved, firmly hold both the
transparent and blue parts of the Mix2Vial™. Unscrew the Mix2Vial™ into two
separate pieces, and discard the empty Water for Injections vial and the blue part of the
Mix2Vial™ in an appropriate waste container.
Note: The Mix2Vial™ is intended to filter the contents of a single vial of Biostate® only. If
multiple vials of Biostate® are to be administered, a separate Mix2Vial™ must be used for
Do not refrigerate Biostate® once it has been reconstituted.
Whilst the physico-chemical stability of the active ingredients has been demonstrated
for 4 hours following reconstitution at room temperature (below 25°C), the product does
not contain an antimicrobial preservative. Therefore it is recommended that the
reconstituted product should be used as soon as practicable. Any unused solution should
be discarded appropriately. Use in one patient on one occasion only. If a clot or gel
forms, do not use the product but return it to the Australian Red Cross Blood Service.
1. With the Biostate® vial upright, attach a plastic disposable syringe to the Mix2Vial™
(transparent plastic part). Invert the system and draw the reconstituted Biostate® into
the syringe by pulling the plunger back slowly. One large syringe may be used to pool
several vials of reconstituted Biostate®.
2. Once the Biostate® has been transferred into the syringe, firmly hold the barrel of the
syringe (keeping the syringe plunger facing down) and detach the Mix2Vial™ from the
syringe. Discard the Mix2Vial™ (transparent plastic part) and empty Biostate® vial in
an appropriate waste container. Fit the syringe to a suitable injection needle to
administer the reconstituted Biostate®. Do not use the Mix2Vial™ for injection.
3. Give the dose slowly (usually within 5 minutes, or as tolerated by the patient) by the
intravenous route. When the contents of more than one vial are to be given, it will be
convenient to pool the total amount prior to administration in a large syringe or sterile
4. To reduce microbiological hazard, use as soon as practicable after
reconstitution/preparation. For use in surgery, the conditions described under
can apply. This product is for single use only and any unused
portion remaining in the vial must be discarded appropriately.
5. The solution must not be added or mixed with any other fluids to be given, including
Medical personnel, family carers and patients should be adequately trained in the techniques
for the preparation and the administration of Biostate®. A detailed and comprehensive
Consumer Medicine Information document is available but this instruction must not take the
place of professional medical advice and supervised training in the administration of Biostate®.
Spillage and breakages
Should a break in the container or spillage occur, due precautions should be taken to avoid
contamination of cuts and abrasions, as well as to avoid inhalation or swallowing of the
spillage. Adequate disinfection can be obtained with the application of 1% sodium
hypochlorite for 15 minutes. Commercial bleaches may be diluted appropriately to obtain this
No symptoms of overdose with human plasma coagulation FVIII/VWF concentrates are
PRESENTATION AND STORAGE CONDITIONS
Biostate® powder for injection is packaged as:
• 250 IU FVIII/500 IU VWF vial of Biostate® (50 IU FVIII/mL, 100 IU VWF/mL),
5 mL vial of Water for Injections, and one Mix2Vial™ filter transfer set
• 500 IU FVIII/1000 IU VWF vial of Biostate® (50 IU FVIII/mL, 100 IU VWF/mL),
10 mL vial of Water for Injections, and one Mix2Vial™ filter transfer set
• 500 IU FVIII/1000 IU VWF vial of Biostate® (100 IU FVIII/mL, 200 IU VWF/mL),
5 mL vial of Water for Injections, and one Mix2Vial™ filter transfer set
Store at 2°C to 8°C (Refrigerate. Do not freeze). Biostate® can be stored below 25°C for a
single period of 6 months. The product must not be returned to refrigeration after storage
below 25°C. Protect from light. Do not use after the expiry date.
NAME AND ADDRESS OF THE SPONSOR
Distributed by: Australian Red Cross Blood Service
POISON SCHEDULE OF THE MEDICINE
Date of first inclusion in the Australian Register of Therapeutic Goods (the
Date of most recent amendment:
26 November 2013
® Biostate is a registered trademark of CSL Limited
™ Mix2Vial is a trademark of West Pharmaceuticals, Inc. or a subsidiary thereof
For Medical/Technical Enquiries:
For Customer Service Enquiries:
Psychiatria Danubina, 2013; Vol. 25, No. 3, pp 266-267 © Medicinska naklada - Zagreb, Croatia DULOXETINE-RELATED GALACTORRHEA AND RESTLESS LEGS SYNDROME: A CASE REPORT Hasan Belli, Mahir Akbudak & Cenk Ural Department of Psychiatry, Bagcilar Education and Research Hospital, Istanbul, Turkey INTRODUCTION weeks. Six weeks later, she applied to our clinic with the compla
Neurodermitis im Kindesalter Die frühzeitige Therapie ist matchentscheidendMARC PLEIMES, PETER SCHMID-GRENDELMEIER, LISA WEIBEL, ZÜRICH Eine grundsätzliche Heilung der Veranlagung zur atopischen Derma- titis ist nicht möglich. Die genetische Disposition besteht lebenslang. Entgegen gängigen Vorstellungen bestehen weiterhin nur bei einem ekzematösen Entzündungsreaktionen.